|
Home
|
|
Symptoms
|
|
Live Discussion
|
|
Diagnosis
|
|
Treatment
|
|
Area Support
|
|
Library
|
|
Research
|
|
Lymelinks
|
|
Contact
|
|
Pets & Lyme
|
|
DONATIONS
|
|
Drug Info
|
|
Medical Dictionary
|
|
Board of Directors
|
|
|
No Warranties or Representations
The data and information presented in this web site are presented in good faith and believed to be accurate. Any and all liability for the content or any omissions including any inaccuracies, errors, or misstatements in such data or information is expressly disclaimed. The web site is compiled for the sole purpose of informing community members of resources and information pertaining to Lyme Borreliosis Disease and its coinfections.
The Canadian Lyme Disease Foundation, Directors and members are not liable for any direct or indirect damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action arising out of or in connection with the use or performance of information available from this website.
Consult a qualified Lyme ( Borreliosis ) Disease literate doctor for medical advice if Lyme Disease is suspect.
|
Immature bacteria fight antibiotics
United Press International
Monday, December 13, 2004
JERUSALEM, Dec 10, 2004 (United Press International via COMTEX) -- Researchers in Israel have discovered that bacteria fight antibiotics by producing slow-growing cells that survive because they are so immature.
A team from Hebrew University in Jerusalem and Rockefeller University in New York say that the "persistent" cells later develop into normal cells that can re-infect a patient. Their research into e-coli bacteria appeared in a recent issue of Science Magazine.
The researchers found that bacteria colonies produce the immature cells constantly whether or not they are under attack.
Nathalie Questembert-Balaban, a professor of biophysics at Hebrew University, said that the research may lead to a solution to the problem of "relapse." She suggested that either antibiotic administration could be timed to hit the persistent cells as they reach maturity or new drugs could be found targeting immature bacteria.
The team's work could also determine why cancer recurs in patients after a successful remission.
|
| | |
